Binding of translationally controlled tumour protein to the N-terminal domain of HDM2 is inhibited by Nutlin-3

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Funston, Garth ^a   Goh, Walter ^b   Wei, Siau Jia ^b   Tng, Quah Soo ^b   Brown, Christopher ^b   Jiah Tong, Loh ^c   Verma, Chandra ^c,d,e   Lane, David ^b   Ghadessy, Farid ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b AGENCY FOR SCIENCE   (Singapore)

^c BIOINFORMATICS INSTITUTE   (Singapore)

^d NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

NUTLIN 3; PROTEIN MDM2; TRANSLATIONALLY CONTROLLED TUMOR PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

AMINO ACID SEQUENCE; CELL LINE; HUMANS; IMIDAZOLES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PIPERAZINES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR MARKERS, BIOLOGICAL;

EID: 84865049831     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042642     Document Type: Article

References (34)

1. Yenofsky R, Cereghini S, Krowczynska A, Brawerman G, (1983) Regulation of mRNA utilization in mouse erythroleukemia cells induced to differentiate by exposure to dimethyl sulfoxide. Mol Cell Biol 3: 1197-1203.
2. Gachet Y, Tournier S, Lee M, Lazaris-Karatzas A, Poulton T, et al. (1999) The growth-related, translationally controlled protein P23 has properties of a tubulin binding protein and associates transiently with microtubules during the cell cycle. J Cell Sci 112 (Pt 8): 1257-1271.
3. Hsu YC, Chern JJ, Cai Y, Liu M, Choi KW, (2007) Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature 445: 785-788.
4. Tuynder M, Susini L, Prieur S, Besse S, Fiucci G, et al. (2002) Biological models and genes of tumor reversion: cellular reprogramming through tpt1/TCTP and SIAH-1. Proc Natl Acad Sci U S A 99: 14976-14981.
5. Yarm FR, (2002) Plk phosphorylation regulates the microtubule-stabilizing protein TCTP. Mol Cell Biol 22: 6209-6221.
6. Bheekha-Escura R, MacGlashan DW, Langdon JM, MacDonald SM, (2000) Human recombinant histamine-releasing factor activates human eosinophils and the eosinophilic cell line, AML14-3D10. Blood 96: 2191-2198.
7. Bommer UA, Thiele BJ, (2004) The translationally controlled tumour protein (TCTP). Int J Biochem Cell Biol 36: 379-385.
8. MacDonald SM, Rafnar T, Langdon J, Lichtenstein LM, (1995) Molecular identification of an IgE-dependent histamine-releasing factor. Science 269: 688-690.
9. Vonakis BM, Sora R, Langdon JM, Casolaro V, MacDonald SM, (2003) Inhibition of cytokine gene transcription by the human recombinant histamine-releasing factor in human T lymphocytes. J Immunol 171: 3742-3750.
10. Adriaenssens E, Lemoine J, El Yazidi-Belkoura I, Hondermarck H, (2002) Growth signaling in breast cancer cells: outcomes and promises of proteomics. Biochem Pharmacol 64: 797-803.
11. Arcuri F, Papa S, Carducci A, Romagnoli R, Liberatori S, et al. (2004) Translationally controlled tumor protein (TCTP) in the human prostate and prostate cancer cells: expression, distribution, and calcium binding activity. Prostate 60: 130-140.
12. Zhu WL, Cheng HX, Han N, Liu DL, Zhu WX, et al. (2008) Messenger RNA expression of translationally controlled tumor protein (TCTP) in liver regeneration and cancer. Anticancer Res 28: 1575-1580.
13. Liu H, Peng HW, Cheng YS, Yuan HS, Yang-Yen HF, (2005) Stabilization and enhancement of the antiapoptotic activity of mcl-1 by TCTP. Mol Cell Biol 25: 3117-3126.
14. Yang Y, Yang F, Xiong Z, Yan Y, Wang X, et al. (2005) An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity. Oncogene 24: 4778-4788.
15. Susini L, Besse S, Duflaut D, Lespagnol A, Beekman C, et al. (2008) TCTP protects from apoptotic cell death by antagonizing bax function. Cell Death Differ 15: 1211-1220.
16. Zhang J, de Toledo SM, Pandey BN, Guo G, Pain D, et al. (2012) Role of the translationally controlled tumor protein in DNA damage sensing and repair. Proc Natl Acad Sci U S A 109: E926-933.
17. Rho SB, Lee JH, Park MS, Byun HJ, Kang S, et al. (2011) Anti-apoptotic protein TCTP controls the stability of the tumor suppressor p53. FEBS Lett 585: 29-35.
18. Amson R, Pece S, Lespagnol A, Vyas R, Mazzarol G, et al. (2011) Reciprocal repression between P53 and TCTP. Nat Med 18: 91-99.
19. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
20. Brown CJ, Dastidar SG, Quah ST, Lim A, Chia B, et al. (2011) C-terminal substitution of MDM2 interacting peptides modulates binding affinity by distinctive mechanisms. PLoS One 6: e24122.
21. Takahashi T, Carbone D, Nau MM, Hida T, Linnoila I, et al. (1992) Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 52: 2340-2343.
22. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501.
23. Uhrinova S, Uhrin D, Powers H, Watt K, Zheleva D, et al. (2005) Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J Mol Biol 350: 587-598.
24. McCoy MA, Gesell JJ, Senior MM, Wyss DF, (2003) Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation. Proc Natl Acad Sci U S A 100: 1645-1648.
25. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, et al. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953.
26. Shimizu H, Burch LR, Smith AJ, Dornan D, Wallace M, et al. (2002) The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J Biol Chem 277: 28446-28458.
27. Ma J, Martin JD, Zhang H, Auger KR, Ho TF, et al. (2006) A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination. Biochemistry 45: 9238-9245.
28. Wallace M, Worrall E, Pettersson S, Hupp TR, Ball KL, (2006) Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol Cell 23: 251-263.
29. Wawrzynow B, Pettersson S, Zylicz A, Bramham J, Worrall E, et al. (2009) A function for the RING finger domain in the allosteric control of MDM2 conformation and activity. J Biol Chem 284: 11517-11530.
30. Thaw P, Baxter NJ, Hounslow AM, Price C, Waltho JP, et al. (2001) Structure of TCTP reveals unexpected relationship with guanine nucleotide-free chaperones. Nat Struct Biol 8: 701-704.
31. Kim M, Jung Y, Lee K, Kim C, (2000) Identification of the calcium binding sites in translationally controlled tumor protein. Arch Pharm Res 23: 633-636.
32. Jung J, Kim M, Kim MJ, Kim J, Moon J, et al. (2004) Translationally controlled tumor protein interacts with the third cytoplasmic domain of Na,K-ATPase alpha subunit and inhibits the pump activity in HeLa cells. J Biol Chem 279: 49868-49875.
33. Chen Y, Fujita T, Zhang D, Doan H, Pinkaew D, et al. (2011) Physical and functional antagonism between tumor suppressor protein p53 and fortilin, an anti-apoptotic protein. J Biol Chem 286: 32575-32585.
34. Joseph TL, Madhumalar A, Brown CJ, Lane DP, Verma CS, (2010) Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies. Cell Cycle 9: 1167-1181.